Clinical trials: Psychotic Disorder
Schizophrenia
Valproate in Late Life Schizophrenia
The purpose of this research study is to analyze the effectiveness and tolerability of a medication, valproate ( Depakote and Depakote ER), in individuals age 50 years and older who have schizophrenia.
- Trial name
- NCT00194025
- Testing
- Valproate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University Hospitals Cleveland Medical Center
Agitation
Treating Acutely Agitated Patients With Asenapine Sublingual Tablets
Our proposal is to administer asenapine to patients who are clinically agitated and in need of immediate intervention. At present there are no controlled studies that we know of that explores the use of asenapine for this…
- Trial name
- NCT01400113
- Testing
- Asenapine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Unity Health Toronto
Schizophrenia, Schizoaffective Disorder
The Effects of Rimonabant, on Weight and Metabolic Risk Factors
1) To examine the efficacy of rimonabant in decreasing weight and metabolic parameters/cardiovascular disease risk in people with schizophrenia receiving second generation antipsychotics 2) To examine the safety and tolerability…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Obesity, Hypertension
- Trial name
- NCT00547118
- Testing
- Rimonabant
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Therapeutic Efficacy of Transcranial Magnetic Stimulation in Schizophrenia
The aim of this study is to look at the effectiveness of repetitive transcranial magnetic stimulation (rTMS) as a therapeutic intervention for patients with schizophrenia.
- Trial name
- NCT01551979
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia; Psychosis
Pharmacological Modulation of Hippocampal Activity in Psychosis 2
The purpose of this study is to test whether administration of levetiracetam (LEV), a commonly used anti-epileptic that alters neurotransmitter release, can reduce hippocampal hyperactivity in people with psychotic disorders.
- Trial name
- NCT04559529
- Testing
- Levetiracetam (LEV) 500 mg
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Major Depressive Disorder, Anxiety
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
The purpose of this study is to investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in subjects with major depressive disorder and anxiety symptoms, who are experiencing an inadequate…
- Trial name
- NCT02013531
- Testing
- Brexpiprazole
- Where
- 21 sites in United States
- Volunteers
- 37 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
- Trial name
- NCT00254202
- Testing
- Iloperidone, Ziprasidone
- Where
- 42 sites in United States, India
- Volunteers
- 593 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
The objective of this study is to assess the safety and efficacy of 3 different doses of CTP-692 administered once daily (QD) for 12 weeks to adult participants with schizophrenia on stable dopaminergic antipsychotic medication.
- Trial name
- NCT04158687
- Testing
- CTP-692
- Where
- 26 sites in United States
- Volunteers
- 326 people
- Sponsor
- Concert Pharmaceuticals
Schizophrenia
Virtual Reality Training for Social Skills in Schizophrenia
Social impairments are core features of schizophrenia that lead to poor outcome. Social skills and competence improve quality of life and protect against stress-related exacerbation of symptoms, while supporting resilience…
- Trial name
- VR-SS (NCT03128099)
- Testing
- Virtual reality social skills training
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Schizophrenia
Study Evaluating Vabicaserin in Subjects With Schizophrenia
The primary purpose of this protocol is to establish the efficacy, safety, and tolerability of vabicaserin (SCA-136) using a once a day capsule in subjects with acute exacerbations of schizophrenia.
- Trial name
- NCT00563706
- Testing
- vabicaserin, risperidone
- Where
- 33 sites in United States, Canada
- Volunteers
- 199 people
- Sponsor
- Pfizer
Schizophrenia With Impulsivity
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity
The purpose of this study is to evaluate the effect of brexpiprazole, via functional magnetic resonance imaging (fMRI), on the right ventrolateral prefrontal cortex (VLPFC) activated by impulsive behavior.
- Trial name
- NCT02194933
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia
The primary aim of the study is to determine the efficacy of adjunctive valacyclovir, in comparison to placebo, to improve visual (Brief Visuospatial Memory Test) and working (composite score of the Spatial Span and Letter Number…
- Trial name
- VISTA (NCT02008773)
- Testing
- Valacyclovir HCI 500 mg tablets
- Where
- 13 sites in United States
- Volunteers
- 170 people
- Sponsor
- Indiana University
Schizophrenia
Effects of Oxytocin Nasal Spray on Social Affiliation
Schizophrenia is a complex and heritable disorder that encompasses several clinical symptom domains and functional impairments. Existing treatments of schizophrenia, although effective against positive symptoms, fail to benefit…
- Trial name
- NCT00663039
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
Schizophrenic Patients in Integrated Care
The purpose of the study is to investigate the well-being of schizophrenic patients treated with quetiapine XR combined with participation in the integrated care program compared to a treatment with quetiapine XR alone over a…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- CARE II (NCT00681629)
- Testing
- Quetiapine XR, Integrated Care Program (ICP)
- Where
- 8 sites in Germany
- Volunteers
- 7 people
- Sponsor
- AstraZeneca
Schizophrenia
Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
The purpose of this study is to determine whether cognitive impairment associated with schizophrenia is attenuated by add-on roflumilast administration to second generation antipsychotics (SGA) in participants with stable…
- Trial name
- NCT02079844
- Testing
- Roflumilast, Second generation antipsychotic
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Takeda
Schizophrenia
Cognitive Behavior Therapy and Work Outcome
This research studies the effects of Cognitive Behavior Therapy and Cognitive Remediation on work for persons with schizophrenia.
- Trial name
- NCT00810355
- Testing
- Support Group, Cognitive Behavior Therapy, Cognitive Remediation
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- VA Office of Research and Development
Schizoaffective Disorder, Schizophrenia
Motivational Interviewing to Improve Work Outcomes in Schizophrenia
Many persons with schizophrenia have difficulty getting and keeping a job. This study is designed to compare the benefits of four sessions of motivational interviewing or illness education in increasing employment rates accruing…
- Trial name
- NCT00261716
- Testing
- IPS, IE, VOMI
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- VA Office of Research and Development
Schizophrenia
Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia
The purpose of this study is to explore the efficacy of flexibly dosed paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality…
- Trial name
- NCT01662648
- Testing
- Paliperidone ER
- Volunteers
- 1,117 people
- Sponsor
- Janssen Pharmaceutica
Schizophrenia, Schizoaffective Disorder
Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder
The study will compare the effectiveness of antipsychotic medications for patients with schizophrenia or schizoaffective disorder for whom a medication change may be indicated because of an increased risk of cardiovascular…
- Trial name
- CAMP (NCT00423878)
- Testing
- Risperidone, Olanzapine, Quetiapine
- Where
- 28 sites in United States
- Volunteers
- 215 people
- Sponsor
- National Institute of Mental Health (NIMH)
Psychosis Prodrome
Ziprasidone in the Psychosis Prodrome
This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
- Trial name
- ZIP (NCT00635700)
- Testing
- ziprasidone
- Where
- 11 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Yale University